Elena Guerra del Río
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena Guerra del Río has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Ginard
Servicio de Aparato Digestivo/IDISBA, Hospital Universitario Son Espases, Palma de Mallorca, España; Miembro de GETECCU
4 shared publications - Manuel Barreiro-De Acosta
Department of Gastroenterology Complexo Hospitalario Universitario de Santiago and Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS) Santiago de Compostela Spain
4 shared publications - Cristina Rodríguez-Gutiérrez
Department of Gastroenterology, Hospital Universitario de Navarra, Pamplona, Spain
3 shared publications - José Luis Cabriada
Department of Gastroenterology, Biobizkaia Health Research Institute, Hospital Universitario de Galdakao-Usansolo, Galdakao, Spain
3 shared publications - Abdel Bouhmidi
Department of Gastroenterology, Hospital Santa Bárbara, 13500 Puertollano, Spain
2 shared publications - Alberto Mir
Department of Gastroenterology, Hospital Ernest Lluch, 50299 Zaragoza, Spain
2 shared publications
Latest Publications
- Open Access
- 6 May 2024
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 47 (10) , 502195
Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study
- 6 May 2024
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 47 (10) , 502195
Open AccessCombination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study
- Open Access
- 23 January 2024
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 47 (7) , 727-733
Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study
- 23 January 2024
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 47 (7) , 727-733
Open AccessCombination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study
- Open Access
- 30 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5816
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885
The authors wish to make the following corrections to this paper
- 30 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5816
Open AccessCorrection: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885
The authors wish to make the following corrections to this paper
- Open Access
- 29 June 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13) , 2885
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.
- 29 June 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13) , 2885
Open AccessIncidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.